ZYBERNO
Stock Report
Updated Aug 31, 2026

Cellectis S.A. (CLLS)

Healthcare • NASDAQ

$3.40

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
Cellectis S.A. (CLLS) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-172.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Cellectis S.A. (CLLS) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.40
Market Cap:$243.95M

Valuation Multiples (3)

P/B Ratio:3.21x
P/S Ratio:3.34x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$182.42M

Price Action & Momentum (3)

Momentum Percentile:91 / 100
% of 52-Week High:70.2%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:71.4%
Fundamental Growth Rate (g):-123.2%

Margin Analysis (1)

Ebitda Margin:-17.8%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):44.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.00x
Quick Ratio:0.00x
Cash Ratio:0.42x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.68x
Times Interest Earned:-1.68

Capital Structure (4)

Working Capital:-145,752,000.00
Cash And Cash Equivalents:61,533,000.00
Long Term Debt:$0.00
Net Debt:-$61.53M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $72.95M
Linear Growth: 44.6%
📊 Click to view full CLLS Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$72.95M-$33.08M

Bottom Line Performance (3)

-$67.59M
Income Before Tax:$0.00
Ebitda Ttm:-13,014,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$65.00K
Interest Expense:19,695,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-17.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$324.72M
Current Assets:$0.00
Ppe Net:38,788,000.00
Goodwill:0.00
Intangible Assets:$535.00K

Liability Structure (4)

Total Liabilities:248,819,000.00
Current Liabilities:145,752,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$75.90M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:17,277,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$39.40M-$41.76M

Investment Activities (1)

Investing Cash Flow:-$29.48M

Financing Activities (3)

Financing Cash Flow:-$16.76M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.94

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.02
Operating Cash Flow Per Share:-$0.55

Book Value & Capital (2)

Book Value Per Share:$1.06
Cash Per Share:0.86

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.22x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:86.45
Cash Conversion Cycle:-2,084.45
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:71.4%
Fundamental Growth Rate (g):-123.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):44.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:CLLS
Company Name:Cellectis S.A.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:71.75M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 01:07:20 UTC
Data Timestamp:2026-08-18T07:21:49.246418
Scroll to Top